Literature DB >> 11601500

Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy.

W K Liu1, T V Le, J Adamson, M Baker, N Cookson, J Hardy, M Hutton, S H Yen, D W Dickson.   

Abstract

Two extended haplotypes of the tau gene (H1 and H2) have been described. The frequency of H1 haplotype is increased in progressive supranuclear palsy (PSP). PSP is associated with filamentous tau lesions in neurons and glia, which are reportedly composed exclusively of tau isoforms with four repeats in the microtubule-binding domain (4R tau). To determine the influence of the tau haplotype on tau isoform composition and neuropathology, we studied 25 PSP cases and 6 Alzheimer's disease patients matched for age, sex, and postmortem delay. In the basal ganglia, tau and amyloid burdens were determined to see if there was an effect of concurrent Alzheimer-type pathology, and the ratio of 4R to 3R tau was measured in detergent-insoluble tau fractions. Insoluble tau from PSP was not composed exclusively of 4R tau. All brains had a mixture of 4R and 3R tau, but the ratio was different in Alzheimer's disease and PSP. In Alzheimer's disease there was less 4R than 3R tau, whereas the ratio was reversed in PSP. In PSP cases with concurrent Alzheimer-type pathology, the ratio of 4R to 3R was intermediate between Alzheimer's disease and PSP. The H1 haplotype had no effect on the 4R to 3R ratio or on tau and amyloid burdens. In summary, the H1 haplotype does not have a major influence on the pathological or biochemical phenotype of PSP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11601500     DOI: 10.1002/ana.1159

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

1.  Differential incorporation of tau isoforms in Alzheimer's disease.

Authors:  Marisol Espinoza; Rohan de Silva; Dennis W Dickson; Peter Davies
Journal:  J Alzheimers Dis       Date:  2008-05       Impact factor: 4.472

Review 2.  The complexity of tau in Alzheimer's disease.

Authors:  Nima N Naseri; Hong Wang; Jennifer Guo; Manu Sharma; Wenjie Luo
Journal:  Neurosci Lett       Date:  2019-04-25       Impact factor: 3.046

3.  Serotonin transporter and saitohin genes in risk of Alzheimer's disease and frontotemporal lobar dementia: preliminary findings.

Authors:  Cristina Lorenzi; Alessandra Marcone; Adele Pirovano; Elena Marino; Francesco Cordici; Chiara Cerami; Dario Delmonte; Stefano F Cappa; Placido Bramanti; Enrico Smeraldi
Journal:  Neurol Sci       Date:  2010-09-18       Impact factor: 3.307

4.  Three-repeat and four-repeat tau isoforms form different oligomers.

Authors:  Hedieh Shahpasand-Kroner; Jennifer Portillo; Carter Lantz; Paul M Seidler; Natalie Sarafian; Joseph A Loo; Gal Bitan
Journal:  Protein Sci       Date:  2022-01-07       Impact factor: 6.993

Review 5.  Tau and MAPT genetics in tauopathies and synucleinopathies.

Authors:  Etienne Leveille; Owen A Ross; Ziv Gan-Or
Journal:  Parkinsonism Relat Disord       Date:  2021-09-14       Impact factor: 4.402

6.  H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers.

Authors:  Elisa Canu; Marina Boccardi; Roberta Ghidoni; Luisa Benussi; Cristina Testa; Michela Pievani; Matteo Bonetti; Giuliano Binetti; Giovanni B Frisoni
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

7.  Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice.

Authors:  Takashi Ishizawa; Narahiko Sahara; Koichi Ishiguro; Jay Kersh; Eileen McGowan; Jada Lewis; Michael Hutton; Dennis W Dickson; Shu-Hui Yen
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

8.  Limbic lobe microvacuolation is minimal in Alzheimer's disease in the absence of concurrent Lewy body disease.

Authors:  Yasuhiro Fujino; Dennis W Dickson
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

9.  White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration.

Authors:  Gabor G Kovacs; Katalin Majtenyi; Salvatore Spina; Jill R Murrell; Ellen Gelpi; Romana Hoftberger; Graham Fraser; R Anthony Crowther; Michel Goedert; Herbert Budka; Bernardino Ghetti
Journal:  J Neuropathol Exp Neurol       Date:  2008-10       Impact factor: 3.685

10.  Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  Erik G Gentry; Benjamin W Henderson; Andrew E Arrant; Marla Gearing; Yangbo Feng; Nicole C Riddle; Jeremy H Herskowitz
Journal:  J Neurosci       Date:  2016-01-27       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.